Google Cloud powered Phagent automates sequencing analysis, facilitates neo-PPI discovery, and closed-loop experimental design in 1–2 weeks.
fast, agnostic, iterative
At MINIMUM bio, we are revolutionizing the landscape of induced proximity therapeutics through our advanced, AI-driven Phagent platform. While companies like MagBio, Rapafusyn, and Revolution Medicines are making significant strides in the field, MINIMUM bio offers a distinct and powerful approach to accelerate the discovery and validation of novel protein-protein interactions (PPIs) and molecular glues.
Connecting proteome-wide phage display biopanning with autonomous bioinformatics, statistical modeling, and next-experiment design.
Unlike traditional discovery pipelines, Phagent leverages sophisticated artificial intelligence to guide, run, and interpret biopanning experiments. This enables us to rapidly identify and validate novel PPIs with unprecedented efficiency—moving beyond serendipitous discovery to a data-driven, predictive approach that integrates multi-omic data, advanced statistical modeling, and machine learning.
MINIMUM bio boasts a cutting-edge rapalog biosynthesis platform, allowing us to generate diverse libraries of rapamycin analogs. Our current focus leverages the well-characterized FKBP family of proteins as versatile carriers, utilizing our proprietary rapalogs as molecular glues to identify clinically relevant neo-PPIs with high precision and speed.
While our initial efforts are centered on FKBP-mediated interactions, the Phagent platform is inherently flexible and agnostic. We are uniquely positioned to discover novel, first-in-class target proteins genome-wide—extending to identifying the targets of any bioactive compound, including small molecules, biologics, PROTACs, and other proximity-inducing medicines.
Our molecular glue discovery platform, powered by phage-displayed human proteome libraries and Phagent automation, enables the rapid identification of first-in-class drug targets, rapalog binders, and FKBP12-mediated interactions within 1–2 weeks. This accelerated timeline significantly reduces the preclinical R&D phase, bringing novel therapies to patients faster.
We are building large libraries of rapalogs for three key discovery pipelines: Oncology, Immunology, and Longevity. Combined with Phagent's ability to synthesize cross-campaign results and propose next-step validation experiments, this targeted approach allows us to address critical unmet medical needs across diverse disease areas.
• Automatically launches end-to-end sequencing pipelines and evaluates human proteome library diversity.
• Tracks clone enrichment across selection rounds and verifies reading-frame integrity.
• Compresses days of manual bioinformatics processing into a streamlined, reproducible workflow completed in minutes.
• Applies advanced statistical modeling and historical cross-campaign memory to strip away non-specific background noise.
• Cross-references enriched proteins against multi-omic and protein-interaction databases.
• Models 3D ternary complexes and domain boundaries to confirm genuine neo-PPIs.
• Synthesizes round-to-round enrichment trajectories, statistical volcano plots, and selectivity heatmaps across campaigns.
• Generates standardized, decision-ready slide decks automatically for MINIMUM bio's team and partners.
• Enables rapid comparison of chemical analogs across Oncology, Immunology, and Longevity targets.
• Evaluates target domain coverage across MINIMUM bio's phage-displayed human proteome libraries.
• Recommends the optimal library and control conditions (such as competition and orthogonal carrier arms).
• Closes the loop between computational discovery and wet-lab validation within our 1–2 week cycle.
MINIMUM bio's Phagent platform represents a new era in induced proximity therapeutics, combining AI-driven discovery with powerful rapalog biosynthesis and phage display platforms to unlock novel biology and deliver transformative medicines.